Plasma cell cancer
Drug research and approvals for plasma cell cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 645 studies of plasma cell cancer are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 645
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- SKCD in Early Relapsed/Refractory Multiple MyelomaNCT07931391 · Phase 2 · Beijing Chao Yang Hospital · starts Oct 31, 2026
- Adjuvant/Neoadjuvant Immunotherapy in Melanoma Based on Serial Plasma ctDNA MonitoringNCT07930182 · Phase 2 · H. Lee Moffitt Cancer Center and Research Institute · starts Oct 21, 2026
- Patient-Specific MRD Liquid Biopsy in Resected NSCLC: Plasma and Bronchial Washing ctDNANCT07921888 · Not reported · Eun Hye Lee · starts Sep 28, 2026
- Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood CancersNCT07914556 · Phase 1 · Mabwell (Shanghai) Bioscience Co., Ltd. · starts Sep 16, 2026
- The Value of a Tailored-based, Exercise Program for Improving Quality of Life of Patients With Hematologic…NCT07912684 · Not applicable · Gruppo Italiano Malattie EMatologiche dell'Adulto · starts Nov 10, 2026
- Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple MyelomaNCT07907211 · Phase 4 · Chen Lijuan · starts Feb 1, 2024
- Plasma DNA Methylation for Preoperative Classification of Renal MassesNCT07874542 · Not reported · RenJi Hospital · starts Sep 1, 2026
- Exercise Phenotyping Prior to Chemotherapy in Newly Diagnosed Multiple Myeloma (MM-Exercise)NCT07851493 · Not reported · Technical University of Munich · starts Sep 1, 2026
- SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell DisordersNCT07850284 · Not reported · Mayo Clinic · starts Aug 25, 2026
Approved 24 of 26
- LenalidomideMultiple myeloma · CRL4(CRBN) E3 ubiquitin ligase inhibitor
- BortezomibMultiple myeloma · 26S proteasome inhibitor
- CyclophosphamideMultiple myeloma · DNA inhibitor
- DaratumumabMultiple myeloma · Lymphocyte differentiation antigen CD38 inhibitor
- PomalidomideMultiple myeloma · CRL4(CRBN) E3 ubiquitin ligase inhibitor
- CarfilzomibMultiple myeloma · 26S proteasome inhibitor
- ThalidomideMultiple myeloma · CRL4(CRBN) E3 ubiquitin ligase inhibitor
- ElotuzumabMultiple myeloma · SLAM family member 7 inhibitor
- IsatuximabMultiple myeloma · Lymphocyte differentiation antigen CD38 inhibitor
- Belantamab mafodotinMultiple myeloma · Tumor necrosis factor receptor superfamily member 17 binding agent
- DoxorubicinMultiple myeloma · DNA topoisomerase II alpha inhibitor
- SelinexorMultiple myeloma · Exportin-1 inhibitor
- PanobinostatMultiple myeloma · Histone deacetylase inhibitor
- PlerixaforMultiple myeloma · C-X-C chemokine receptor type 4 partial agonist
- TeclistamabMultiple myeloma · T cell surface glycoprotein CD3 binding agent
- Zoledronic acidMultiple myeloma · Farnesyl diphosphate synthase inhibitor
- ElranatamabMultiple myeloma · T cell surface glycoprotein CD3 binding agent
- IbrutinibWaldenstrom macroglobulinemia · Tyrosine-protein kinase BTK inhibitor
- TalquetamabMultiple myeloma · T cell surface glycoprotein CD3 binding agent
- CarmustineMultiple myeloma · Glutathione reductase inhibitor
- Idecabtagene vicleucelMultiple myeloma · Tumor necrosis factor receptor superfamily member 17 binding agent
- Melphalan flufenamideMultiple myeloma · DNA cross-linking agent
- ZanubrutinibWaldenstrom macroglobulinemia · Tyrosine-protein kinase BTK inhibitor
- Ciltacabtagene autoleucelMultiple myeloma · Tumor necrosis factor receptor superfamily member 17 binding agent
Phase 3 12 of 57
- DexamethasoneMultiple myeloma · Glucocorticoid receptor agonist
- FilgrastimMultiple myeloma · Granulocyte colony stimulating factor receptor agonist
- PrednisoneMultiple myeloma · Glucocorticoid receptor agonist
- IxazomibMultiple myeloma · 26S proteasome inhibitor
- FludarabineMultiple myeloma
- BusulfanMultiple myeloma · DNA inhibitor
- RituximabWaldenstrom macroglobulinemia · B-lymphocyte antigen CD20 binding agent
- BendamustineMultiple myeloma · DNA inhibitor
- IberdomideMultiple myeloma · CRL4(CRBN) E3 ubiquitin ligase modulator
- VorinostatMultiple myeloma · Histone deacetylase 1 inhibitor
- Mycophenolate mofetilMultiple myeloma · Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- ClarithromycinMultiple myeloma · Bacterial 70S ribosome inhibitor
Phase 2 12 of 168
- TacrolimusMultiple myeloma · FK506-binding protein 1A inhibitor
- Arsenic trioxideMultiple myeloma · Thioredoxin reductase 1 inhibitor
- MethotrexateMultiple myeloma · Dihydrofolate reductase inhibitor
- Ascorbic acidMultiple myeloma · Supplement
- SirolimusMultiple myeloma · FK506-binding protein 1A inhibitor
- TocilizumabMultiple myeloma · Interleukin-6 receptor alpha subunit inhibitor
- NirogacestatMultiple myeloma · Gamma-secretase inhibitor
- EverolimusMultiple myeloma · FK506-binding protein 1A inhibitor
- AzacitidineMultiple myeloma · DNA (cytosine-5)-methyltransferase 3A inhibitor
- CevostamabMultiple myeloma
- TretinoinMultiple myeloma · Retinoic acid receptor agonist
- AldesleukinMultiple myeloma · Interleukin-2 receptor agonist
Phase 1 or earlier 12 of 194
- OprozomibMultiple myeloma · 26S proteasome inhibitor
- HydroxychloroquineMultiple myeloma · Ferriprotoporphyrin IX inhibitor
- IpilimumabMultiple myeloma · Cytotoxic T-lymphocyte protein 4 inhibitor
- MaplirpaceptMultiple myeloma
- CabozantinibMultiple myeloma · Vascular endothelial growth factor receptor 2 inhibitor
- LGH-447Multiple myeloma · Serine/threonine-protein kinase PIM inhibitor
- AtezolizumabMultiple myeloma · Programmed cell death 1 ligand 1 inhibitor
- TipifarnibMultiple myeloma · Protein farnesyltransferase inhibitor
- DacetuzumabMultiple myeloma · Tumor necrosis factor receptor superfamily member 5 inhibitor
- Indatuximab ravtansineMultiple myeloma · Syndecan-1 binding agent
- MezagitamabMultiple myeloma · Lymphocyte differentiation antigen CD38 binding agent
- RicolinostatMultiple myeloma · Histone deacetylase 6 inhibitor
How its trials ended
2,879 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 841 whose ending is known, 36% met their primary endpoint, 4% missed it and 60% stopped early.
- Completed, result not reported97434%
- Ongoing79127%
- Met its primary endpoint30110%
- Status unknown2739%
- Stopped: other or unclear2318%
- Stopped: enrollment or feasibility1395%
- Stopped: sponsor or business decision753%
- Stopped: lack of efficacy351%
- Missed its primary endpoint341%
- Stopped: safety14<1%
- Stopped: funding12<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA